Clinical Trials on Squamous-Cell Non-Small-Cell Lung Cancer

Total 16385 results

Western Regional Medical Center

Terminated

Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer | Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer

United States
AIO-Studien-gGmbH
AstraZeneca

Terminated

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)

NSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR Mutation

Germany
Peking University First Hospital
Merck Sharp & Dohme LLC

Not yet recruiting

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung Cancer

China
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic...

United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

Spain, Italy, Poland, Brazil, Turkey, Serbia, France, Korea, Republic of, Romania, Hungary, Russian Federation, United States, United Kingdom, Germany, Greece, Japan, Thailand, Ukraine, China
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...

United States
European Organisation for Research and Treatment...

Withdrawn

Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) (SOLUTION)

Squamous Non-small Cell Lung Cancer | Non-Squamous Non-small Cell Lung Cancer
Bristol-Myers Squibb

No longer available

Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169)

Non-squamous Non-Small Cell Lung Cancer | Squamous Non-Small Cell Lung Cancer

Brazil, Canada
Eli Lilly and Company

Withdrawn

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Metastatic Squamous Non-Small Cell Lung Cancer | Locally Advanced Squamous Non-Small Cell Lung Cancer

Italy, Romania, Germany, Belgium, Russian Federation, United States, United Kingdom
Mythic Therapeutics

Recruiting

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung Cancer

United States, Australia, Korea, Republic of, United Kingdom
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

Philippines, Thailand, France, Korea, Republic of, Hong Kong, United States, Turkey, Malaysia, Taiwan, Brazil, Serbia, Greece, Slovakia, Peru, South Africa, Mexico, Vietnam, Bangladesh
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Singapore, Hong Kong, Canada
Calithera Biosciences, Inc

Terminated

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Squamous Non-small-cell Lung Cancer | NFE2L2 Gene Mutation | Squamous Non-Small Cell Neoplasm of Lung

United States
Calithera Biosciences, Inc

Terminated

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

Non-Small Cell Lung Cancer | Non-squamous Non-small-cell Lung Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | KEAP1 Gene Mutation | NFE2L2 Gene Mutation | NRF2 Mutation

United States
Sung Yong Lee
Yuhan Corporation

Recruiting

A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy (PLATINUM)

Non-small Cell Lung Cancer Stage III | Non-squamous Non-small-cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
National Cancer Institute (NCI)

Recruiting

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial

Lung Non-Small Cell Carcinoma | Lung Non-Small Cell Squamous Carcinoma | Lung Non-Squamous Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8

United States, Guam
Intergroupe Francophone de Cancerologie Thoracique

Completed

Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer (MODEL)

Non Small Cell Lung Cancer (Squamous or Non Squamous)

France
Seagen Inc.
Merck Sharp & Dohme LLC

Terminated

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Melanoma | Small Cell Lung Cancer | Prostate Cancer | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Adenocarcinoma | Non-small Cell Lung Cancer, Squamous | Non-small Cell Lung Cancer, Non-squamous

United States, Korea, Republic of, Italy, United Kingdom, Australia, Taiwan
Sidney Kimmel Cancer Center at Thomas Jefferson...
Bristol-Myers Squibb

Completed

Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Stage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...

United States
Genentech, Inc.

Completed

A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers

United States, Netherlands
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC

Lung Cancer | Non Small Cell Lung Cancer | Metastatic Lung Cancer | Advanced Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | Squamous Cell Lung Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Boehringer Ingelheim

Completed

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Stage III Non-small Cell Lung Cancer

United States
Calithera Biosciences, Inc

Terminated

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE)

Non-Small Cell Lung Cancer | Non-squamous Non-small-cell Lung Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | KEAP1 Gene Mutation | NRF2 Gene Mutation | NFE2L2 Gene Mutation

United States
Peking University People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

EGFR Positive Non-small Cell Lung Cancer | Non Squamous Non Small Cell Lung Cancer
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer

Unspecified Adult Solid Tumor, Protocol Specific | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer
University of Pittsburgh
National Institutes of Health (NIH)

Terminated

LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer

Pulmonary Disease, Chronic Obstructive | Head and Neck Squamous Cell Cancer | Non-Small-Cell Lung Carcinoma

United States
BIND Therapeutics

Completed

A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer

Squamous Cell Non-small Cell Lung Cancer | KRAS Positive Patients With Non-small Cell Lung Cancer

United States, Russian Federation
M.D. Anderson Cancer Center

Terminated

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIC Lung Cancer AJCC v8 | Unresectable Lung... and other conditions

United States
University Health Network, Toronto
AstraZeneca

Withdrawn

A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME)

Squamous Cell Carcinoma of Head and Neck | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma

Canada
National Cancer Institute (NCI)

Completed

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
Incyte Corporation
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)

Metastatic Squamous Non-Small Cell Lung Cancer | Metastatic Nonsquamous Non-Small Cell Lung Cancer

China, Czechia, Russian Federation, Serbia, Malaysia, Vietnam, United States, Poland, Ukraine, Romania, Turkey, Brazil, Bulgaria, Georgia, Hungary, Philippines, South Africa
Francisco Robert,MD
Sanofi; Bayer

Terminated

Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC

Non Small Cell Lung Cancer | Non Squamous Cell Lung Cancer

United States
Jonsson Comprehensive Cancer Center
Novartis; Translational Research in Oncology

Completed

Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer

United States
Sinocelltech Ltd.

Terminated

SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer

Squamous-cell Non-Small-cell Lung Cancer

China
Amgen

Active, not recruiting

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (FORTITUDE-201)

Squamous-Cell Non-Small-Cell Lung Cancer

France, Belgium, Spain, United States, Taiwan, Korea, Republic of, Japan, Poland
Swiss Group for Clinical Cancer Research

Terminated

Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)

Squamous-cell Non-small Cell Lung Cancer

Switzerland
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

Squamous Cell Non-small Cell Lung Cancer

United States, Italy, France, Germany
Imugene Limited

Active, not recruiting

A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV | Squamous Non-small-cell Lung Cancer | Large Cell Carcinoma Lung | Adenocarcinoma Lung

United States, Australia
Loma Linda University

Terminated

Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer

United States
Henan Provincial People's Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC (ALTER-L025)

Non-squamous Cell Non-Small Cell Lung Cancer

China
Bristol-Myers Squibb

Completed

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate057)

Non-Squamous Cell Non-small Cell Lung Cancer

United States, Germany, Hong Kong, Spain, Australia, Mexico, Austria, France, Singapore, Switzerland, Canada, Poland, Argentina, Brazil, Chile, Czechia, Hungary, Italy, Norway, Peru, Romania, Russian Federation
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer

Advanced Non-squamous Cell Non-small Cell Lung Cancer

China
Shanghai JMT-Bio Inc.

Not yet recruiting

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Squamous Cell Non-small Cell Lung Cancer
Bristol-Myers Squibb

Completed

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)

Squamous Cell Non-small Cell Lung Cancer

United States, France, Chile, Australia, Netherlands, Argentina, Austria, Canada, Czechia, Germany, Hungary, Ireland, Italy, Mexico, Norway, Peru, Poland, Romania, Russian Federation, Spain, United Kingdom
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditions

United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ） (neoSCORE Ⅱ)

Squamous Cell Non-small Cell Lung Cancer

China
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC

Non-squamous Cell Non-Small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Non-squamous Non-small-cell Lung Cancer

China
National Hospital Organization Nagoya Medical Center
Merck Sharp & Dohme LLC; Central Japan Lung Study Group

Active, not recruiting

Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

Non-squamous Non-small-cell Lung Cancer | Cancer, Lung

Japan

Clinical Trials on Squamous-Cell Non-Small-Cell Lung Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations